Option chain shows key data for Exicure's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Exicure.

Exicure (NASDAQ:XCUR) Stock, Option Chain

Exicure

Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.

Palantir, Salesforce, Okta, Meta, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

BOXL

BWNB

COGT

DATS

GDTC

GETY

GORO

HCWC

KUKE

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

NARI

RIME

SBEV

SLRN

SYRA

XCUR

XTIA

Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket

marvell technology shutter

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BSLK

CNEY

CRGY

CTNT

ENSC

ESGL

GSX Techedu Inc. American Depositary Shares

GOTU

HRTX

HTOO

LUNR

MRVL

ORIS

PSTG

SOAR

TANH

VIRX

Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Netflix, TSMC, American Express, Moderna, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

AKTS

ALLT

APTO

ARQQ

CDXC

DBGI

ELAB

KULR

LION

NIVF

Nuveen California Dividend Advantage Municipal Fund 2

QMCO

QUBT

RGTI

UXIN

XTKG

Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Exicure Inc

Curate

Press Releases

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Chardan Capital

Comments

Exicure

Exicure (XCUR) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga